-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
-
Summary
-
Halozyme Therapeutics, Inc. quarterly/annual Amortization of Intangible Assets history and growth rate from Q2 2021 to Q2 2024.
- Halozyme Therapeutics, Inc. Amortization of Intangible Assets for the quarter ending June 30, 2024 was $17.8M, a 0.41% decline year-over-year.
- Halozyme Therapeutics, Inc. Amortization of Intangible Assets for the twelve months ending June 30, 2024 was $73.6M, a 9.22% increase year-over-year.
- Halozyme Therapeutics, Inc. annual Amortization of Intangible Assets for 2023 was $73.8M, a 71% increase from 2022.
- Halozyme Therapeutics, Inc. annual Amortization of Intangible Assets for 2022 was $43.1M.
- Halozyme Therapeutics, Inc. annual Amortization of Intangible Assets for 2021 was $0.000.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Growth (%)